GE Healthcare Acquires Producer of Nanofibers

UK: Nanofibre Technology GE Healthcare Acquires Producer of Nanofibers

30.11.2017Editor: MA Alexander Stark

GE Healthcare has completed the acquisition of Puridify, a bioprocessing start-up that is developing a nanofiber-based platform purification technology for biopharmaceutical production. Puridify’s technology, Fibro Select, is complementary to the bead resins and chromatography membranes used today in downstream bioprocessing.

Related Vendors

GE Healthcare Europe GmbH

KNF Neuberger GmbH

Puridify’s technology, Fibro Select, is complementary to the bead resins and chromatography membranes used today in downstream bioprocessing,
(Source: GE Healthcare)

Chalfont St Giles/UK — The company has collaborated with several major biopharmaceutical manufacturers in the development of their technology. The platform is expected to bring productivity improvements in the process development (PD) phase and small-scale manufacturing for a wide variety of biopharmaceutical applications. GE Healthcare will invest further to bring the platform to commercialization fully integrating it within the broad range of bioprocess purification products already available at GE.

GE will acquire Puridify and all 17 employees will join GE Healthcare Life Sciences’ Bio Process business. The Puridify team will remain at their current location in Stevenage, UK, which will serve as a small research hub for Bio Process. Since it was founded in 2014 and after winning the first One Start competition, Puridify has been privately funded by leading venture capital investors Touchstone Innovations and SR One, with additional support from University College London (UCL) Business.

Assistant Professor Tan Swee Ching (left), Mr Sai Kishore Ravi (right) and their team from the National University of Singapore's Faculty of Engineering has developed a novel nanofibre solution. (National University of Singapore)

“The technology that Puridify has been developing gives GE access to exciting technology that could give considerable improvements for some customers in their purification step. The early feedback from collaborators has been positive. Today’s investment in this new technology is further evidence of GE’s strong commitment to innovation in the production of biopharmaceuticals to the benefit of our customers and of patients world-wide,” said Jan Makela, General Manager, Bio Process, GE Healthcare Life Sciences.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:45032617)